<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154524">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01660191</url>
  </required_header>
  <id_info>
    <org_study_id>12943</org_study_id>
    <nct_id>NCT01660191</nct_id>
  </id_info>
  <brief_title>A Study Comparing CoQ10 Levels While Taking 3 Different Statins</brief_title>
  <acronym>SPARQ</acronym>
  <official_title>A Study Comparing the Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on Plasma Levels of CoQ10 (SPARQ)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kowa Pharmaceuticals America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if Pitavastatin lowers CoQ10 less than
      Atorvastatin or Rosuvastatin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Statins are known effectively treat high cholesterol and heart disease.  However, statins
      may lower endogenous levels of Coenzyme10 (CoQ10).  This decrease in CoQ10 levels may be
      responsible for side effects such as myalgia.

      Previous studies have shown that Pitavastatin may not affect CoQ10 levels as other statins
      do, while still lowering cholesterol.

      In this study, investigators intend to compare the plasma levels of CoQ10 in patients taking
      3 different FDA-approved statins, in equipotent doses.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Changes in plasma CoQ10 levels</measure>
    <time_frame>Change from Baseline to 12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in levels will be measured by levels at 12 weeks minus levels at baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in major lipid parameters</measure>
    <time_frame>Change from Baseline to 12 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in levels will be measured by levels at 12 weeks minus levels at baseline.  Major lipid parameters include apoA1, apoB, LDL and HDL particle number and size.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes to glucose metabolism</measure>
    <time_frame>Change from Baseline to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in levels will be measured by levels at 12 weeks minus levels at baseline.  Changes measured based in HbA1c, frusctosamine, insulin, and proinsulin.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Pitavastatin 4mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 20mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>rosuvastatin 5 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Statin</intervention_name>
    <description>Pitavastatin 4mg, Atorvastatin 20mg, or rosuvastatin 5mg, once daily by mouth for 12 weeks</description>
    <arm_group_label>Pitavastatin 4mg</arm_group_label>
    <arm_group_label>Atorvastatin 20mg</arm_group_label>
    <arm_group_label>rosuvastatin 5 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  LDL-C levels of 100-200mg/dl; triglycerides &lt;/=200mg/dl at screening visit

          -  Willing to discontinue use of all lipid-altering doses fo medication or supplements
             for the duration of the study

        Exclusion Criteria:

          -  LDL-C &lt;100mg/dl or &gt;200mg/dl, Triglycerides &gt;200mg/dl

          -  History of diabetes mellitus or documented fasting blodo glucose &gt;125mg/dl or HbA1c
             &gt;6.4%

          -  History of coronary artery disease

          -  history of chrinic renal or hepatic disease

          -  known sensitivity of intolerance to a statin

          -  persistent elevated liver enzymes or CPK (&gt;3 x upper normal limit)

          -  currently taking CoQ10 supplements and unable discontinue for duration of study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick M Moriarty, MD, FACC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 3, 2014</lastchanged_date>
  <firstreceived_date>May 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas</investigator_affiliation>
    <investigator_full_name>Patrick Moriarty, MD, FACP, FACC</investigator_full_name>
    <investigator_title>Director, Atherosclerosis &amp; LDL-Apheresis Center</investigator_title>
  </responsible_party>
  <keyword>LDL, HDL</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
    <mesh_term>Rosuvastatin</mesh_term>
    <mesh_term>Pitavastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
